PPIs are frequently targeted with small molecules, monoclonal antibodies (mAb) or peptidomimetics. The peptidomimetics can be developed starting from a peptide sequence either protein uses to interact. Alternatively, screening technics (e.g., fragment-based, high through-put or in silico screening) could be used to develop small molecule inhibitors.